Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Genelux's Business Segments
Genelux's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Operating Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Operating Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Operating Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Operating Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Operating Segment | - | - |
Description of Genelux
Genelux Corporation is a biotechnology company that specializes in the development and commercialization of cutting-edge oncolytic viral therapies for the treatment of cancer. The company was founded in 2007 and is headquartered in San Diego, California.
At its core, Genelux aims to revolutionize cancer treatment by leveraging the power of viruses to specifically target and kill cancer cells while leaving normal cells unharmed. Their flagship platform is based on a proprietary modified vaccinia virus Ankara (MVA) vector, which has been engineered to selectively infect and destroy cancer cells.
The MVA platform is highly versatile and allows for the incorporation of additional gene modifications to enhance the therapeutic effects of the virus. This includes the insertion of genes encoding therapeutic proteins, such as cytokines or immune checkpoint inhibitors, to stimulate the immune response against cancer cells or modulate the tumor microenvironment.
Genelux has developed a pipeline of oncolytic viruses tailored to different types of cancer, including breast, lung, colorectal, pancreatic, melanoma, and ovarian cancers. Each virus is designed to target specific molecular markers or genetic mutations that are commonly found in these cancer types, ensuring a high degree of selectivity and efficacy.
One of the key advantages of Genelux's viral therapies is their ability to replicate within cancer cells, leading to the release of more virus particles and amplification of the therapeutic effect. Furthermore, the infected cancer cells will eventually burst, releasing tumor antigens that can stimulate an immune response and enhance the long-term anti-cancer effects.
In addition to its oncolytic virus programs, Genelux is also engaged in research collaborations with leading academic institutions and pharmaceutical companies to explore the potential of its viral platform in combination with other therapies, such as chemotherapy, radiation, or immune checkpoint inhibitors.
The company has a strong focus on translational medicine, with a dedicated team of scientists and clinicians working towards advancing its therapies from preclinical studies to clinical trials. Genelux has successfully completed several phase I and phase II clinical trials demonstrating the safety and efficacy of its oncolytic viral therapies in various cancer indications.
To support the development and commercialization of its therapies, Genelux has established strategic partnerships and licensing agreements with pharmaceutical companies, providing access to additional resources and expertise. These collaborations aim to accelerate the regulatory approval and global distribution of Genelux's viral therapies.
Overall, Genelux Corporation is an innovative biotechnology company at the forefront of oncolytic viral therapy. Its unique approach has the potential to revolutionize cancer treatment by providing a targeted and personalized therapeutic option that harnesses the power of the immune system to fight cancer.
At its core, Genelux aims to revolutionize cancer treatment by leveraging the power of viruses to specifically target and kill cancer cells while leaving normal cells unharmed. Their flagship platform is based on a proprietary modified vaccinia virus Ankara (MVA) vector, which has been engineered to selectively infect and destroy cancer cells.
The MVA platform is highly versatile and allows for the incorporation of additional gene modifications to enhance the therapeutic effects of the virus. This includes the insertion of genes encoding therapeutic proteins, such as cytokines or immune checkpoint inhibitors, to stimulate the immune response against cancer cells or modulate the tumor microenvironment.
Genelux has developed a pipeline of oncolytic viruses tailored to different types of cancer, including breast, lung, colorectal, pancreatic, melanoma, and ovarian cancers. Each virus is designed to target specific molecular markers or genetic mutations that are commonly found in these cancer types, ensuring a high degree of selectivity and efficacy.
One of the key advantages of Genelux's viral therapies is their ability to replicate within cancer cells, leading to the release of more virus particles and amplification of the therapeutic effect. Furthermore, the infected cancer cells will eventually burst, releasing tumor antigens that can stimulate an immune response and enhance the long-term anti-cancer effects.
In addition to its oncolytic virus programs, Genelux is also engaged in research collaborations with leading academic institutions and pharmaceutical companies to explore the potential of its viral platform in combination with other therapies, such as chemotherapy, radiation, or immune checkpoint inhibitors.
The company has a strong focus on translational medicine, with a dedicated team of scientists and clinicians working towards advancing its therapies from preclinical studies to clinical trials. Genelux has successfully completed several phase I and phase II clinical trials demonstrating the safety and efficacy of its oncolytic viral therapies in various cancer indications.
To support the development and commercialization of its therapies, Genelux has established strategic partnerships and licensing agreements with pharmaceutical companies, providing access to additional resources and expertise. These collaborations aim to accelerate the regulatory approval and global distribution of Genelux's viral therapies.
Overall, Genelux Corporation is an innovative biotechnology company at the forefront of oncolytic viral therapy. Its unique approach has the potential to revolutionize cancer treatment by providing a targeted and personalized therapeutic option that harnesses the power of the immune system to fight cancer.
Genelux Corporation is a biotechnology company focused on the development of innovative gene therapies and immunotherapies, primarily for the treatment of cancers. The company specializes in creating oncolytic virus platforms, which harness the power of modified viruses to specifically target and destroy cancer cells while sparing normal cells. This unique approach leads to a multicompartmental method of treatment that not only directly destroys tumors but can also elicit a systemic immune response.
Segments
Genelux operates within the following core segments:
1. Oncolytic Virus Therapies: This segment is central to Genelux’s mission. The company develops a variety of genetically modified oncolytic viruses designed to selectively infect and kill cancer cells. These therapies aim to exploit the unique biology of tumors, allowing for both localized and systemic therapeutic effects.
2. Gene Therapy Collaboration: Genelux collaborates with academic and industry partners to advance the field of gene therapy. These partnerships often focus on combining gene therapies with existing treatment modalities, such as chemotherapy or checkpoint inhibitors, to improve patient outcomes.
3. Immuno-Oncology: This segment emphasizes enhancing the body’s immune response to cancer. Through innovative platforms, Genelux seeks to develop therapies that can activate and expand the immune system’s ability to recognize and eliminate cancer cells.
4. Preclinical and Clinical Development: Genelux actively pursues research that transitions their findings from the laboratory into clinical applications. This encompasses early-stage development of novel therapeutic candidates through to late-stage clinical trials.
Products
Genelux Corporations product pipeline includes:
1. GL-ONC1: This is one of the company’s flagship products, an oncolytic adenovirus that selectively targets tumor cells. It is currently undergoing clinical trials for various cancers, with a focus on determining its efficacy and safety.
2. GL-ONC2: Similar to GL-ONC1, this therapy is another engineered adenovirus designed to treat solid tumors. It incorporates advanced therapeutic modalities to enhance the anti-tumor immune response.
3. Combination Therapies: Genelux is exploring the synergy between its oncolytic virus therapies and other cancer treatments. By combining these therapies with immunotherapies or targeted therapies, the company aims to improve efficacy across a range of cancers.
Services
In addition to its product offerings, Genelux provides various services including:
1. Research & Development Services: Genelux offers R&D services that encompass preclinical studies, model development, and clinical trial design to partners interested in developing oncolytic virus therapies or related treatment modalities.
2. Consultative Expertise: The company provides consultative services to other biotech firms and research institutions looking to leverage oncolytic virus technology for their cancer therapeutics.
3. Collaborative Partnerships: Genelux actively engages in strategic partnerships with pharmaceutical companies and academic institutions to share knowledge, resources, and insights in the realm of cancer research and development.
4. Regulatory Support: With extensive experience navigating regulatory pathways for novel biotherapeutics, Genelux offers guidance and support regarding FDA interactions, clinical trial applications, and compliance with therapeutic guidelines.
Conclusion
Genelux Corporation continues to innovate within the biopharmaceutical space with a focus on developing unique therapies to treat cancer. Through its extensive pipeline of oncolytic viruses, combination therapies, collaborative services, and regulatory expertise, Genelux aims to significantly impact the landscape of cancer treatment by providing more effective and targeted therapeutic options for patients. The company’s commitment to research and development in gene and immunotherapy positions it as a key player in the fight against cancer.
Segments
Genelux operates within the following core segments:
1. Oncolytic Virus Therapies: This segment is central to Genelux’s mission. The company develops a variety of genetically modified oncolytic viruses designed to selectively infect and kill cancer cells. These therapies aim to exploit the unique biology of tumors, allowing for both localized and systemic therapeutic effects.
2. Gene Therapy Collaboration: Genelux collaborates with academic and industry partners to advance the field of gene therapy. These partnerships often focus on combining gene therapies with existing treatment modalities, such as chemotherapy or checkpoint inhibitors, to improve patient outcomes.
3. Immuno-Oncology: This segment emphasizes enhancing the body’s immune response to cancer. Through innovative platforms, Genelux seeks to develop therapies that can activate and expand the immune system’s ability to recognize and eliminate cancer cells.
4. Preclinical and Clinical Development: Genelux actively pursues research that transitions their findings from the laboratory into clinical applications. This encompasses early-stage development of novel therapeutic candidates through to late-stage clinical trials.
Products
Genelux Corporations product pipeline includes:
1. GL-ONC1: This is one of the company’s flagship products, an oncolytic adenovirus that selectively targets tumor cells. It is currently undergoing clinical trials for various cancers, with a focus on determining its efficacy and safety.
2. GL-ONC2: Similar to GL-ONC1, this therapy is another engineered adenovirus designed to treat solid tumors. It incorporates advanced therapeutic modalities to enhance the anti-tumor immune response.
3. Combination Therapies: Genelux is exploring the synergy between its oncolytic virus therapies and other cancer treatments. By combining these therapies with immunotherapies or targeted therapies, the company aims to improve efficacy across a range of cancers.
Services
In addition to its product offerings, Genelux provides various services including:
1. Research & Development Services: Genelux offers R&D services that encompass preclinical studies, model development, and clinical trial design to partners interested in developing oncolytic virus therapies or related treatment modalities.
2. Consultative Expertise: The company provides consultative services to other biotech firms and research institutions looking to leverage oncolytic virus technology for their cancer therapeutics.
3. Collaborative Partnerships: Genelux actively engages in strategic partnerships with pharmaceutical companies and academic institutions to share knowledge, resources, and insights in the realm of cancer research and development.
4. Regulatory Support: With extensive experience navigating regulatory pathways for novel biotherapeutics, Genelux offers guidance and support regarding FDA interactions, clinical trial applications, and compliance with therapeutic guidelines.
Conclusion
Genelux Corporation continues to innovate within the biopharmaceutical space with a focus on developing unique therapies to treat cancer. Through its extensive pipeline of oncolytic viruses, combination therapies, collaborative services, and regulatory expertise, Genelux aims to significantly impact the landscape of cancer treatment by providing more effective and targeted therapeutic options for patients. The company’s commitment to research and development in gene and immunotherapy positions it as a key player in the fight against cancer.